| Description | Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up to 3 nM and is inhibitory to PD-1/PD-L1 with an IC50 of 0.70 nM.Camrelizumab exhibits anti-tumor activity and is well tolerated in the study cancers including NSC-LC, ESCC, Hodgkin's lymphoma and advanced HCC. |
| In vitro | 在使用结核菌素处理的外周血单个核细胞进行的T细胞增殖实验中，Camrelizumab以EC50为0.11 nM诱导T细胞增殖。在另一项测量IFN-γ分泌的类似实验中，Camrelizumab以EC50为0.38 nM诱导IFN-γ产生。[2] |
| In vivo | 在人源PD-1转基因小鼠模型中，Camrelizumab（3 mg/kg）与阿帕替尼（200 mg/kg 和 100 mg/kg）联合使用，肿瘤抑制率分别达到了63.1%和87.3%的。[1] |
| Target activity | PD-1/PD-L1:0.70 nM (IC50) |
| Synonyms | SHR-1210, Camrelizumab（anti-PD-1） |
| molecular weight | N/A |
| CAS | 1798286-48-2 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| References | 1. Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191. 2. Lickliter JD, et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther. 2020;14:1177-1189. 3. Caicun Zho, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021 Mar;9(3):305-314. |